AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 2.45
(3.38%)
SEK 2.45
(3.38%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.22 Million SEK | -20.54% |
| 2022 | 10.35 Million SEK | -18.3% |
| 2021 | 12.67 Million SEK | 79.2% |
| 2020 | 7.07 Million SEK | 48.95% |
| 2019 | 4.74 Million SEK | 2.93% |
| 2018 | 4.61 Million SEK | 11.26% |
| 2017 | 4.14 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 7.88 Million SEK | -9.58% |
| 2024 Q1 | 8.71 Million SEK | 5.97% |
| 2023 Q4 | 8.22 Million SEK | 19.82% |
| 2023 Q1 | 6.99 Million SEK | -32.41% |
| 2023 FY | 8.22 Million SEK | -20.54% |
| 2023 Q2 | 6.93 Million SEK | -0.91% |
| 2023 Q3 | 6.86 Million SEK | -0.98% |
| 2022 Q4 | 10.35 Million SEK | 19.59% |
| 2022 Q3 | 8.65 Million SEK | -30.05% |
| 2022 Q2 | 12.37 Million SEK | -10.89% |
| 2022 Q1 | 13.89 Million SEK | 9.6% |
| 2022 FY | 10.35 Million SEK | -18.3% |
| 2021 Q4 | 12.67 Million SEK | -0.26% |
| 2021 FY | 12.67 Million SEK | 79.2% |
| 2021 Q2 | 9.93 Million SEK | -11.91% |
| 2021 Q3 | 12.7 Million SEK | 27.96% |
| 2021 Q1 | 11.27 Million SEK | 59.39% |
| 2020 FY | 7.07 Million SEK | 48.95% |
| 2020 Q4 | 7.07 Million SEK | -28.27% |
| 2020 Q1 | 8.18 Million SEK | 72.35% |
| 2020 Q2 | 10.12 Million SEK | 23.76% |
| 2020 Q3 | 9.85 Million SEK | -2.65% |
| 2019 Q4 | 4.74 Million SEK | 20.08% |
| 2019 Q3 | 3.95 Million SEK | -10.01% |
| 2019 Q2 | 4.39 Million SEK | -5.99% |
| 2019 FY | 4.74 Million SEK | 2.93% |
| 2019 Q1 | 4.67 Million SEK | 1.32% |
| 2018 Q3 | 2.54 Million SEK | 0.0% |
| 2018 FY | 4.61 Million SEK | 11.26% |
| 2018 Q4 | 4.61 Million SEK | 81.4% |
| 2018 Q1 | - SEK | -100.0% |
| 2017 FY | 4.14 Million SEK | 0.0% |
| 2017 Q4 | 4.14 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcuCort AB | 10.97 Million SEK | 25.039% |
| BioGaia AB (publ) | 302.84 Million SEK | 97.283% |
| Enzymatica AB (publ) | 49.3 Million SEK | 83.313% |
| Enorama Pharma AB (publ) | 14.84 Million SEK | 44.588% |
| Gabather AB (publ) | 6.87 Million SEK | -19.613% |
| Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | 74.279% |
| Moberg Pharma AB (publ) | 24 Million SEK | 65.731% |
| Nanexa AB (publ) | 36.42 Million SEK | 77.415% |
| Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | 78.88% |
| ODI Pharma AB | 10.05 Million SEK | 18.202% |
| Orexo AB (publ) | 727.7 Million SEK | 98.869% |
| Probi AB (publ) | 181.31 Million SEK | 95.463% |
| Swedencare AB (publ) | 2.31 Billion SEK | 99.645% |
| Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 99.98% |
| Toleranzia AB | 6.9 Million SEK | -19.077% |
| Vivesto AB | 30.45 Million SEK | 72.984% |